The FDA has approved more than 40 cellular and gene therapy (CGT) products to date. However, there is a lack of regulation to mitigate the risks these new treatments pose to healthcare workers, according to a paper in the American Journal of Health-System Pharmacy. The authors proposed standard operating procedures (SOPs) for handling emerging therapies to protect pharmacists who come into contact with these new compounds as they grow in number and availability (2025 Feb 6.
MAY 23, 2025